Business Context and Reporting Period
Company: CorMedix Inc. (CRMD)
Filing Type: Form 10-Q (Unaudited)
Period: Quarter and six months ended June 30, 2024
Business Overview: CorMedix is a biopharmaceutical company focused on commercializing DefenCath, an antimicrobial catheter lock solution approved by the FDA in November 2023. The product was launched commercially in the U.S. inpatient setting in April 2024 and the outpatient setting in July 2024. The company is classified as a smaller reporting company and a non-accelerated filer.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2024 |
Six Months Ended June 30, 2024 |
Six Months Ended June 30, 2023 |
|---|---|---|---|
| Net Sales | $806 | $806 | $0 |
| Cost of Sales | $(510) | $(1,328) | $0 |
| Gross Profit (Loss) | $296 | $(522) | $0 |
| Operating Expenses | $(15,597) | $(31,483) | $(22,822) |
| Net Loss | $(14,151) | $(28,618) | $(21,841) |
| Net Loss Per Share (Basic/Diluted) | $(0.25) | $(0.50) | $(0.49) |
| Cash and Cash Equivalents | $28.5 million (as of June 30, 2024) | ||
| Short-term Investments | |||
| Total Liquidity (Cash + Investments) | $45.6 million (as of June 30, 2024) | ||
| Total Liabilities | $11.5 million (as of June 30, 2024) |
Material Changes vs. Prior Period
- Revenue Generation: The company recorded $806,000 in net sales for the three and six months ended June 30, 2024, compared to zero revenue in the same periods in 2023, following the commercial launch of DefenCath.
- Operating Expenses: Total operating expenses increased by 38% year-over-year for the six-month period ($31.5M vs. $22.8M).
- Selling and Marketing: Increased 133% to $13.7M due to the commercial launch, sales force build-out, and marketing efforts.
- General and Administrative: Increased 87% to $16.3M, driven by personnel expenses and legal/compliance costs.
- Research and Development: Decreased 82% to $1.5M as costs shifted to commercial operations and manufacturing costs were capitalized or moved to cost of sales.
- Net Loss: Net loss increased by 31% for the six-month period to $28.6M, primarily due to the significant increase in operating expenses associated with the commercial launch.
- License Intangible Asset: The company recorded a $2.0 million license intangible asset and corresponding liability in Q2 2024, related to probable achievement of net sales milestones under its license agreement with ND Partners, LLP.
Guidance, Outlook, Risks, and Unusual Items
- Liquidity Outlook: Management estimates that existing cash, cash equivalents, and short-term investments ($45.6 million) are sufficient to fund operations for at least twelve months from the filing date. The company expects to continue generating operating cash flow deficits until significant revenue is achieved.
- Capital Resources: Approximately $48.8 million remains available under the 2024 At-The-Market (ATM) program, and $100 million remains under the 2024 Shelf Registration Statement. In March 2024, the company received $1.4 million from the sale of New Jersey net operating losses.
- Reimbursement Status:
- Inpatient: DefenCath received a New Technology Add-On Payment (NTAP) of up to $17,111 per hospital stay. The company anticipates CMS will revise this to reflect the actual Wholesale Acquisition Cost (WAC) of $249.99 per vial in the next rulemaking (effective Oct 1, 2024).
- Outpatient: Received Transitional Drug Add-On Payment Adjustment (TDAPA) approval effective July 1, 2024. Also received pass-through status under the Outpatient Prospective Payment System (OPPS) for separate Medicare Part B payment.
- Legal Proceedings: The company is involved in consolidated securities class action litigation and shareholder derivative litigation regarding alleged misstatements related to DefenCath's NDA submissions and FDA communications. The company intends to vigorously contest these claims.
- Unusual Items: Recorded $500,000 in "Other Income" during the quarter from a vendor settlement. Additionally, a $2.0 million liability was accrued for license milestone payments deemed probable.
Investor Verification Checklist
- Revenue Concentration: Verify the sustainability of revenue given that 100% of Q2 2024 sales came from a single customer.
- Reimbursement Adjustments: Monitor the October 2024 CMS rulemaking to confirm the revised NTAP payment amount based on the actual WAC of $249.99.
- Legal Exposure: Track the status of the securities class action and derivative litigation, specifically the court's ruling on the motion to dismiss filed in June 2024.
- Supply Chain: Confirm progress on qualifying alternative suppliers for key APIs (taurolidine and heparin) and the additional manufacturing site (Siegfried Hameln) to mitigate single-source risks.
- Cash Burn Rate: Assess the runway of the $45.6 million liquidity position against the current burn rate of approximately $14.5 million per quarter to determine the need for additional financing.